MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer
MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer
复制标题
DOI：
10.26355/eurrev_201910_19282
复制
发表时间：
2019-01-01
影响因子：
3.3
通讯作者：
Cai, Y-D
中科院分区：
文献类型：
--
作者：
Ke, J.;Zhang, B-H;Cai, Y-D
目的：MIR-1作为一种抑制性microRNA在胃癌中发挥作用。本研究旨在探讨miR-1-3p靶向stanniocalcin 2(STC2)抑制胃癌进展的机制。方法：采用实时定量聚合酶链式反应(qRT-PCR)检测miR-1-3p在胃癌组织中的表达水平。采用定量逆转录聚合酶链式反应(qRT-PCR)和Western印迹分析检测STC2的表达。用四甲基偶氮唑蓝(3-(4，5-二甲基噻唑-2-基)-2，5-二苯基四氮唑溴化法)和Transwell法检测细胞增殖和侵袭能力。分别进行了分析。结果：miR-1-3p在胃癌中的表达明显下调。更有甚者。MiR-1-3p的异常表达与胃癌的大小有关。在功能上，miR-1-3p的过表达通过抑制stanniocalcin2(STC2)的表达抑制了GC的增殖和侵袭。相比之下。STC2在胃癌中的表达显著上调。此外，miR-1-3p负调控胃癌中STC2的表达。STC2的上调减弱了miR-1-3p对胃癌细胞的抑制作用。结论：miR-1-3p通过靶向胃癌中的STC2抑制细胞的增殖和侵袭。为GC提供了一个新的治疗靶点。
OBJECTIVE: MiR-1 has been reported to act as an inhibitory microRNA in gastric cancer (GC). This study aimed to investigate the regulatory mechanism by which miR-1-3p blocks the progression of GC by targeting stanniocalcin 2 (STC2).PATIENTS AND METHODS: The expression level of miR-1-3p in GC was assessed via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Expressions of STC2 were measured by qRT-PCR and Western blot analysis. Proliferation and invasion assays were detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assays. respectively. Moreover, the dual-luciferase reporter assay was used to confirm the binding sites between miR-1-3p and STC2.RESULTS: MiR-1-3p was significantly down-regulated in GC. Moreover. abnormal expression of miR-1-3p was correlated with GC tumor size. Functionally, overexpression of miR-1-3p inhibited proliferation and invasion in GC by inhibiting stanniocalcin 2 (STC2) expressions. In contrast. STC2 was significantly up-regulated in GC. Furthermore, miR-1-3p negatively regulated STC2 expression in GC. The upregulation of STC2 weakened the inhibitory effect of miR-1-3p in GC.CONCLUSIONS: MiR-1-3p suppressed cell proliferation and invasion by targeting STC2 in GC. providing a novel therapeutic target for GC.